Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5944565 | 0.86 | HDAC8 (0.39) | SMN1; SMN2HTTACHEAPOBEC3AAPOBEC3G | |
| SCHEMBL3458701 | 0.81 | SMN1; SMN2 (0.36) | SMN1; SMN2HTTLMNAHPGDACHE | |
| SCHEMBL5297687 | 0.81 | LMNA (0.38) | SMN1; SMN2HTTLMNAHPGDACHE | |
| SCHEMBL3458261 | 0.81 | MAPT (0.42) | CTDSP1MAPT | |
| SCHEMBL3458197 | 0.79 | APOBEC3A (0.45) | SMN1; SMN2HTTAPOBEC3AAPOBEC3GKDM4E | |
| SCHEMBL5287483 | 0.78 | HTT (0.36) | SMN1; SMN2HTTLMNAHPGDHDAC8 | |
| SCHEMBL486703 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2HTTLMNAHPGDACHE | |
| SCHEMBL5296950 | 0.76 | HTT (0.36) | SMN1; SMN2HTTLMNAHPGDAPOBEC3A | |
| SCHEMBL5815544 | 0.75 | HTT (0.39) | SMN1; SMN2HTTLMNAHPGDAPOBEC3A | |
| SCHEMBL5291240 | 0.75 | HTT (0.39) | SMN1; SMN2HTTLMNAHPGDAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100321863-A1 | ACTIVATED CARBON AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-7785495-B2 | Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| EP-2093191-A1 | ACTIVATED CARBON AND METHOD FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20090103241-A1 | Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1905740-A1 | ELECTRIC DOUBLE LAYER CAPACITOR | Sumitomo Chemical Company, Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-20060186419-A1 | Light-emitting device | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090103241-A1 | Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 | CBR1, CYP24A1, CALU | SMN1; SMN2 4879/4885HTT 4854/4885LMNA 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.